Stem-cell therapy

Global Stem Cell Therapy Market Report 2020-2030 Featuring Major Players | Anterogen, JCR, Medipost, Osiris Therapeutics, Pharmicell, Astellas, Cellectis, Celyad, Novadip Biosciences and Gamida Cell

Retrieved on: 
Thursday, January 7, 2021
Life sciences, Branches of biology, Biology, Stem cells, Biotechnology, Cell biology, Emerging technologies, Cell therapy, Stem-cell therapy, Cellectis, Astellas Pharma, Therapy

Stem Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global stem cell therapy market.

Key Points: 
  • Stem Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global stem cell therapy market.
  • Major players in the stem cell therapy market are Anterogen, JCR Pharmaceuticals, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences and Gamida Cell.
  • The stem cell therapy market consists of the sales of stem cell therapy and related services by entities (organizations, sole traders, and partnerships) that provide stem cell therapy.
  • The stem cell therapy market covered in this report is segmented by type into allogeneic stem cell therapy; autologous stem cell therapy.

ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients

Retrieved on: 
Wednesday, January 6, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Stem cells, Regenerative biomedicine, Developmental biology, Cell therapy, Placebo, Mesoblast, Stem-cell therapy

The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells intravenously at days 0 and 3, and 12 additional patients received placebo control.

Key Points: 
  • The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells intravenously at days 0 and 3, and 12 additional patients received placebo control.
  • At 28 days 91% of JadiCell treated patients survived whereas only 42% of patients in the placebo group survived.
  • "The ImmCelz regenerative immunotherapy product is a personalized cellular therapy generated by co-culture of patient's immune cells with stem cells.
  • The ImmCelz cell therapy product has demonstrated efficacy in animal models of stroke, heart failure, autoimmunity, and liver failure.

Global Stem Cell Therapy Market Report 2020-2030 with COVID-19 Impacts, Growth and Changes - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology, Health, Stem cells, Branches of biology, Articles, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Life extension, Stem-cell therapy, Cell therapy, Therapy, Science, technology, engineering, and mathematics

Stem Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global stem cell therapy market.

Key Points: 
  • Stem Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global stem cell therapy market.
  • The stem cell therapy market consists of the sales of stem cell therapy and related services by entities (organizations, sole traders, and partnerships) that provide stem cell therapy.
  • The stem cell therapy market covered in this report is segmented by type into allogeneic stem cell therapy; autologous stem cell therapy.
  • The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market.

Global Cell Therapy Market Report 2020: Market to Recover in 2023

Retrieved on: 
Thursday, December 31, 2020
Branches of biology, Life sciences, Biology, Cell biology, Biotechnology, Stem cells, Emerging technologies, Medicinal chemistry, Therapy, Cell therapy, Stem-cell therapy, Adoptive cell transfer

Cell Therapy Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.

Key Points: 
  • Cell Therapy Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.
  • The cell therapy market consists of sales of cell therapy and related services.
  • The cell therapy market covered in this report is segmented by technique into stem cell therapy; cell vaccine; adoptive cell transfer (ACT); fibroblast cell therapy; chondrocyte cell therapy.
  • Therefore, the high cost of cell therapy restraints the growth of the cell therapy market.

Global Cell Therapy Market Report 2020-2030 with COVID-19 Growth and Change - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 23, 2020
Oncology, Health, Infectious diseases, Diabetes, Genetics, Managed care, Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Emerging technologies, Connective tissue cells, Cell therapy, Stem-cell therapy, Therapy, Chondrocyte

The "Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.
  • The cell therapy market covered in this report is segmented by technique into stem cell therapy; cell vaccine; adoptive cell transfer (ACT); fibroblast cell therapy; chondrocyte cell therapy.
  • Therefore, the high cost of cell therapy restraints the growth of the cell therapy market.

Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention

Retrieved on: 
Wednesday, December 16, 2020
Branches of biology, Biology, Stem cells, Biotechnology, Obesity, Connective tissue, Cell biology, Adipose tissue, SVF, Stromal cell, Stem-cell therapy

Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.

Key Points: 
  • Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.
  • The two parties aim to file an Investigational New Drug (IND) application to the FDA for initiating a clinical trial in patients at high risk of suicide.
  • "We are highly impressed by the superior speed, viability, and quality of SVF cells obtained using the Synova Life Sciences device as compared to other collagenase-based approaches.
  • "I look forward at working with the Team at Therapeutic Solutions International in advancing this novel utility of adipose derived stem cells," said John Chi, President and CEO of Synova Life Sciences.

Global Stem Cell Therapy Market (2020 to 2025) - Players Include Biotime, Sanbio and Bluerock Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 8, 2020
Health, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, ASEAN, Southeast Asia, Compound annual growth rate, Stem-cell therapy

This report describes the global market size of Stem Cell Therapy from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.

Key Points: 
  • This report describes the global market size of Stem Cell Therapy from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.
  • For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
  • The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
  • For the competitor segment, the report includes global key players of Stem Cell Therapy as well as some small players.

Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS")

Retrieved on: 
Tuesday, December 8, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Developmental biology, Mesenchymal stem cell, Induced pluripotent stem cell, Stem-cell therapy, Cell therapy

As previously announced, Citius signed an exclusive worldwide licensing agreement with Novellus Therapeutics Limited to develop and commercialize iPSC-derived i-MSCs.

Key Points: 
  • As previously announced, Citius signed an exclusive worldwide licensing agreement with Novellus Therapeutics Limited to develop and commercialize iPSC-derived i-MSCs.
  • In conjunction with the licensing agreement, the Company established a new subsidiary, NoveCite, Inc., to develop, manufacture and commercialize these induced mesenchymal stem cells.
  • NoveCite's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process.
  • i-MSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19.

Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, December 8, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Biology, Stem cells, Glial cells, Life sciences, Biotechnology, Biology of bipolar disorder, Oligodendrocyte, Lineage Cell Therapeutics, Stem-cell therapy, Spinal Cord Injuries, OPC1, the OPC1 Clinical Study, Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).
  • The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with acute spinal cord injuries (SCI).
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Global Regenerative Medicine Market Research Report 2020

Retrieved on: 
Friday, December 4, 2020
Branches of biology, Biology, Life sciences, Stem cells, Emerging technologies, Regenerative biomedicine, Life extension, Stem-cell therapy, Regenerative medicine, Cell therapy, Regenerative medicine

DUBLIN, Dec. 4, 2020 /PRNewswire/ -- The "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 4, 2020 /PRNewswire/ -- The "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.
  • Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products.
  • The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period
    Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.